Scientific Publications of the American Heart Association

Cardiovascular Metabolic Imaging: Physiologic and Biochemical Dynamics In Vivo

Jeanie B. McMillin-Wood, James B. Bassingthwaighte (eds.)

This report is a summary of presentations, discussions, and recommendations made in September 1984 at a workshop held in Bethesda, Md. Fifty-eight basic scientists and clinical investigators in biochemistry, physiology, cardiology, nuclear medicine, and physics met to discuss dilemmas and directions in metabolic imaging. Discussion centered on development of imaging techniques for application to cardiovascular and pulmonary studies in health and disease. The Division of Heart and Vascular Diseases of the National Heart, Lung, and Blood Institute sponsored the conference, which was held in facilities provided by the American College of Cardiology. Supplement to Circulation, November 1985. Monograph No. 115, soft cover, 171 pp.

Order No. 73-101-A $6

To order use this coupon

☐ Check enclosed (Make payable to the American Heart Association)
Send me ______ copies of Cardiovascular Metabolic Imaging: Physiologic and Biochemical Dynamics In Vivo at $6 each. (73-101-A)

NAME

STREET

CITY

STATE       ZIP CODE

MAIL TO: American Heart Association
National Center
7220 Greenville Avenue
Dallas, Texas 75231
The presence of hypertension and diabetes mellitus, which commonly occur together, may increase the risk of cardiovascular and renal complications. Such complications lead to early death or disability in the majority of diabetic patients. In their preface to this supplement, the editors wrote, "Considering the prevalence, clinical importance, and prognostic relevance of both hypertension and diabetes mellitus, the pathogenesis and treatment of their particular association deserve intensified investigation." It is the intent of these proceedings, drawn from a conference held in Switzerland in June 1984, to stimulate research and provide practical information. The proceedings are of particular interest to cardiovascular physicians, diabetologists, and nephrologists. Supplement to Hypertension, November/December 1985. Monograph No. 117, soft cover, 174 pp.
NITROSTAT®
(nitroglycerin tablets, USP)
Before prescribing, please see full prescribing information.
A Brief Summary follows:

INDICATIONS
Nitroglycerin is indicated for the prophylaxis, treatment and management of patients with angina pectoris.

CONTRAINDICATIONS
Sublingual nitroglycerin therapy is contraindicated in patients with early myocardial infarction, severe anemia, increased intracranial pressure, and those with a known hypersensitivity to nitroglycerin.

PRECAUTIONS
Only the smallest dose required for effective relief of the acute anginal attack should be used. Excessive use may lead to the development of tolerance. Nitrostat tablets are intended for sublingual or buccal administration and should not be swallowed. The drug should be discontinued if blurring of vision or drying of the mouth occurs. Excessive dosage of nitroglycerin may produce severe headaches.

ADVERSE REACTIONS
Transient headache may occur immediately after use. Vertigo, weakness, palpitation, and other manifestations of postural hypotension may develop occasionally, particularly in erect, immobile patients. Syncope due to nitrate vasodilation has been reported. Alcohol may accentuate the cerebral ischemia symptoms.

METHOD OF ADMINISTRATION
One tablet should be dissolved under the tongue or in the buccal pouch at the first sign of an acute anginal attack. The dose may be repeated approximately every five minutes until relief is obtained. Nitrostat may be used prophylactically five to ten minutes prior to engaging in activities which might precipitate an acute attack.

HOW SUPPLIED
Nitrostat is supplied in four strengths in bottles containing 100 tablets each, with color-coded labels, and in color-coded Patient Convenience Packages of four bottles of 25 tablets each.

0.15 mg (1/400 grain):
N 0071-0568-24—Bottle of 100 tablets,
N 0071-0568-13—Convenience Package

0.3 mg (1/200 grain):
N 0071-0569-24—Bottle of 100 tablets,
N 0071-0569-13—Convenience Package

0.4 mg (1/150 grain):
N 0071-0570-24—Bottle of 100 tablets,
N 0071-0570-13—Convenience Package

0.6 mg (1/100 grain):
N 0071-0571-24—Bottle of 100 tablets,
N 0071-0571-13—Convenience Package.

PARKE-DAVIS
Div of Warner-Lambert Co
Morris Plains, NJ 07950
NATURE HAS A WAY OF PROTECTING ITS OWN.

So does NITROSTAT®
(nitroglycerin tablets, USP)

Just by the way it's made, NITROSTAT too, has built-in protection—protection against loss of nitroglycerin. In fact, NITROSTAT is more stable than conventional nitroglycerin tablets under all conditions of temperature and humidity tested.

But that's not all. Average assay still shows better than 100% of label claim for at least 60 months after manufacture of NITROSTAT. Because of this stability NITROSTAT has a five-year expiration date.*

What's more, only NITROSTAT Tablets are available in convenient packages of 4 x 25 tablets. So emergency angina relief can be ready when needed in four different locations. “Because of its rapid action, long-established efficacy, and low cost, nitroglycerin is the most useful drug among the organic nitrates that can be given sublingually”" NITROSTAT... useful alone or as concomitant therapy with long-acting nitrates or propranolol.

*Five-year expiration date when stored at recommended storage conditions in an unopened bottle. Data on file. Medical Affairs Dept. Parke Davis.


Please see preceding page for brief summary of prescribing information.

PARKE-DAVIS
Division of Warner-Lambert Company
Morr& Plains, New Jersey 07950